Osmotica Pharmaceuticals plc (OSMT)’s Financial Results Comparing With Radius Health Inc. (NASDAQ:RDUS)

As Biotechnology companies, Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and Radius Health Inc. (NASDAQ:RDUS) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osmotica Pharmaceuticals plc 274.34M 1.50 6.40M -0.13 0.00
Radius Health Inc. 72.48M 12.16 251.26M -5.57 0.00

Table 1 highlights Osmotica Pharmaceuticals plc and Radius Health Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Osmotica Pharmaceuticals plc -2.33% 0% 0%
Radius Health Inc. -346.66% -150.2% -65.2%

Liquidity

The current Quick Ratio of Osmotica Pharmaceuticals plc is 1.1 while its Current Ratio is 1.3. Meanwhile, Radius Health Inc. has a Current Ratio of 5.5 while its Quick Ratio is 5.4. Radius Health Inc. is better positioned to pay off its short-term and long-term debts than Osmotica Pharmaceuticals plc.

Analyst Recommendations

The Recommendations and Ratings for Osmotica Pharmaceuticals plc and Radius Health Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Osmotica Pharmaceuticals plc 0 0 0 0.00
Radius Health Inc. 0 0 2 3.00

Meanwhile, Radius Health Inc.’s consensus target price is $54.5, while its potential upside is 181.65%.

Institutional and Insider Ownership

Institutional investors owned 37% of Osmotica Pharmaceuticals plc shares and 0% of Radius Health Inc. shares. About 41.8% of Osmotica Pharmaceuticals plc’s share are owned by insiders. Insiders Competitively, owned 0.26% of Radius Health Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Osmotica Pharmaceuticals plc -0.38% -11% 0% 0% 0% -3.68%
Radius Health Inc. -4.32% -8.54% -15.11% -41.45% -41.81% -49.8%

For the past year Osmotica Pharmaceuticals plc’s stock price has smaller decline than Radius Health Inc.

Summary

On 8 of the 11 factors Osmotica Pharmaceuticals plc beats Radius Health Inc.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.